SYN-AKE

Overview

SYN-AKE is a synthetic tripeptide developed by DSM Nutritional Products (formerly Pentapharm) that mimics the activity of Waglerin-1, a 22-amino-acid neurotoxic peptide isolated from the venom of the Temple Viper (Tropidolaemus wagleri). Introduced to the cosmetics market in 2005, SYN-AKE was designed to reduce facial expression lines by reversibly antagonizing the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction, thereby decreasing muscle fiber contraction.

The concept of biomimetic cosmetic peptides derived from animal venoms represented a novel approach in cosmetic science. While Argireline and Snap-8 target the presynaptic SNARE complex to reduce neurotransmitter release, SYN-AKE operates postsynaptically by competing with acetylcholine for binding at the muscle-type nicotinic receptor. This mechanistic distinction positions SYN-AKE as a complementary rather than redundant approach to neuromuscular wrinkle reduction.

The compound attracted considerable media attention upon launch, with the snake venom association providing a compelling marketing narrative. SYN-AKE has since become a staple ingredient in premium anti-aging formulations and is frequently combined with presynaptic-targeting peptides for multi-level neuromuscular modulation.

Structure

SYN-AKE is a modified tripeptide with non-proteinogenic amino acid components:

Chemical name: Dipeptide Diaminobutyroyl Benzylamide Diacetate

• Molecular formula: C₂₈H₄₁N₅O₆ (diacetate salt)
• Molecular weight: 563.66 g/mol (diacetate salt)
• CAS Number: 823202-99-9
• INCI name: Dipeptide Diaminobutyroyl Benzylamide Diacetate
• Origin: Synthetic; pharmacophore inspired by Waglerin-1 from Tropidolaemus wagleri venom

The structure incorporates a diaminobutyric acid residue and a C-terminal benzylamide group, which together create the minimal pharmacophore required for nAChR binding. The molecule was designed through structure-activity relationship studies that identified the essential binding elements within the much larger native Waglerin-1 toxin, then synthesized as a stable, non-toxic tripeptide retaining receptor affinity.

The parent toxin Waglerin-1 (sequence: GGKPDLRPCHPPCHYIPRPKPR) contains a disulfide-bridged loop structure critical for its high-affinity receptor binding. SYN-AKE does not replicate this full structure but captures the key electrostatic and hydrophobic interactions necessary for reversible, low-affinity nAChR antagonism.

Mechanism of Action

Nicotinic Acetylcholine Receptor Antagonism

At the neuromuscular junction, acetylcholine released from motor nerve terminals binds to muscle-type nicotinic acetylcholine receptors (nAChRs) on the postsynaptic membrane. Receptor activation opens cation channels, producing an endplate potential that triggers muscle fiber contraction.

SYN-AKE competes with acetylcholine for binding at the nAChR orthosteric site. By occupying a fraction of available receptors, the peptide reduces the amplitude of the endplate potential, leading to:

• Decreased force of muscle contraction
• Reduced dynamic folding of overlying skin
• Progressive smoothing of expression lines with continued application

This mechanism parallels that of curare-type neuromuscular blockers (competitive antagonists), though SYN-AKE is applied topically at cosmetic concentrations far below those producing clinically significant muscle weakness.

Distinction from Presynaptic Mechanisms

The postsynaptic site of action differentiates SYN-AKE from the SNARE-targeting peptides:

This mechanistic complementarity supports the rationale for combining presynaptic and postsynaptic peptides in multi-peptide anti-wrinkle formulations.

Reversibility and Safety Margin

SYN-AKE's receptor binding is fully reversible and of substantially lower affinity than therapeutic neuromuscular blocking agents. The cosmetic concentrations used (typically 1-4% of commercial solution) are designed to produce subtle modulation of muscle tone rather than functional paralysis. No systemic neuromuscular effects have been reported in clinical evaluations of topical SYN-AKE formulations.

Research Summary

Applications

Cosmetic Use

SYN-AKE is formulated in premium anti-aging products at typical concentrations of 1-4% of the commercial solution (peptide in a standardized vehicle). Key product categories include:

• Anti-wrinkle serums and creams targeting expression lines of the forehead, glabella, and periorbital region
• Premium anti-aging systems where the "snake venom peptide" positioning supports luxury brand narratives
• Multi-peptide formulations combining postsynaptic (SYN-AKE) and presynaptic (Argireline, Snap-8) mechanisms with ECM stimulators (Matrixyl)

The compound is stable across a pH range of 4.0-7.0 and is compatible with most cosmetic matrices including oil-in-water emulsions, hydrogels, and serum bases.

Multi-Mechanism Wrinkle Strategies

The rationale for combining SYN-AKE with presynaptic neuromuscular peptides rests on pharmacological synergy: simultaneous reduction of neurotransmitter release (presynaptic) and receptor availability (postsynaptic) should produce greater net muscle relaxation than either approach alone. When further combined with collagen-stimulating peptides, these multi-peptide formulations address both the dynamic and structural components of facial wrinkle formation.

Consumer Perception

The snake venom origin story has proven to be a powerful marketing asset for SYN-AKE. The concept of harnessing and taming a natural venom mechanism resonates with consumers interested in biomimetic and nature-derived cosmetic science, even though the synthetic tripeptide bears minimal structural resemblance to the full native toxin.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a topical cosmetic peptide.

Application notes: Apply to clean skin, focusing on areas with expression lines (forehead, crow's feet, glabella). Stable across pH 4.0-7.0. Often combined with presynaptic neuromuscular peptides (Argireline, Snap-8) for dual-mechanism wrinkle reduction, and with collagen-stimulating peptides (Matrixyl) for comprehensive anti-aging protocols. Consistent use for 4-8 weeks is recommended before evaluating results.

Related Compounds

• Argireline — a hexapeptide SNARE complex inhibitor operating at the presynaptic terminal; mechanistically complementary to SYN-AKE
• Snap-8 — an extended octapeptide version of Argireline with enhanced SNARE disruption; also presynaptic in mechanism
• Matrixyl — a collagen-stimulating pentapeptide addressing structural wrinkle depth through ECM remodeling
• Palmitoyl Tripeptide-1 — a matrikine peptide stimulating collagen and elastin production
• Waglerin-1 — the full 22-amino-acid venom peptide from Tropidolaemus wagleri that served as the template for SYN-AKE's design